In vivo activation of STAT3 in cutaneous T-cell lymphoma.: Evidence for an antiapoptotic function of STAT3

被引:139
作者
Sommer, VH
Clemmensen, OJ
Nielsen, O
Wasik, M
Lovato, P
Brender, C
Eriksen, KW
Woetmann, A
Kaestel, CG
Nissen, MH
Ropke, C
Skov, S
Odum, N
机构
[1] Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen N, Denmark
[2] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark
[3] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] Univ Copenhagen, Copenhagen, Denmark
关键词
CTCL; STAT3; neoplastic transformation; in vivo; apoptosis;
D O I
10.1038/sj.leu.2403385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A characteristic feature of neoplastic transformation is a perpetual activation of oncogenic proteins. Here, we studied signal transducers and activators of transcription ( STAT) in patients with mycosis fungoides (MF)/cutaneous T-cell lymphoma ( CTCL). Malignant lymphocytes in dermal infiltrates of CTCL tumors showed frequent and intense nuclear staining with anti-PY-STAT3 antibody, indicating a constitutive activation of STAT3 in vivo in tumor stages. In contrast, only sporadic and faint staining was observed in indolent lesions of patch and plaque stages of MF. Moreover, neoplastic lymphocytes in the epidermal Pautrier abscesses associated with early stages of MF did not express activated STAT3. To address the role of STAT3 in survival/ apoptosis, CTCL tumor cells from an advanced skin tumor were transfected with either wild-type STAT3 (STAT3wt) or dominant-negative STAT3 (STAT3D). Forced inducible expression of STAT3D triggered a significant increase in tumor cells undergoing apoptosis, whereas forced expression of STAT3wt or empty vector had no effect. In conclusion, a profound in vivo activation of STAT3 is observed in MF tumors but not in the early stages of MF. Moreover, STAT3 protects tumor cells from apoptosis in vitro. Taken together, these findings suggest that STAT3 is a malignancy factor in CTCL.
引用
收藏
页码:1288 / 1295
页数:8
相关论文
共 33 条
[11]   Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis [J].
Fukada, T ;
Hibi, M ;
Yamanaka, Y ;
TakahashiTezuka, M ;
Fujitani, Y ;
Yamaguchi, T ;
Nakajima, K ;
Hirano, T .
IMMUNITY, 1996, 5 (05) :449-460
[12]   Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo [J].
Grandis, JR ;
Drenning, SD ;
Zeng, Q ;
Watkins, SC ;
Melhem, MF ;
Endo, S ;
Johnson, DE ;
Huang, L ;
He, YK ;
Kim, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) :4227-4232
[13]  
Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348
[14]  
Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847
[15]   The Jak-STAT pathway: Cytokine signalling from the receptor to the nucleus [J].
Heim, MH .
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1999, 19 (1-4) :75-120
[16]  
KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161
[17]   Negative regulators of cytokine signaling [J].
Kile, BT ;
Nicola, NA ;
Alexander, WS .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (03) :292-298
[18]   Cutaneous T-cell lymphoma [J].
Kotz, EA ;
Anderson, D ;
Thierst, BH .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2003, 17 (02) :131-137
[19]   STATs: Transcriptional control and biological impact [J].
Levy, DE ;
Darnell, JE .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (09) :651-662
[20]   What does Stat3 do? [J].
Levy, DE ;
Lee, CK .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1143-1148